BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Industry Leader ThalesNano Delivers 500th H-Cube to Prestigious Institute in China


4/28/2010 1:09:55 PM

BEIJING, BUDAPEST, HUNGARY, and LONDON--(Marketwire - April 27, 2010) -

ThalesNano Inc. announced that it has delivered its 500th H-Cube. Citing reasons of safety, efficiency and ease of use, the Beijing Institute of Technology has recently purchased the 500th H-Cube flow hydrogenation system built by ThalesNano Inc.

Since its launch in 2004, sales of the H-Cube have grown substantially every year as scientists worldwide have experienced the great benefits it offers over traditional batch methodologies used for hydrogenation.

Professor Li of the Beijing Institute of Technology said, "The H-Cube is becoming recognized in China as the new standard for bench top Hydrogenation. Utilizing this technology will make a significant impact on the efficiency of our research efforts and help us to stay in the forefront of chemistry. It will also help us to make chemical transformations that are difficult or impossible with traditional technologies."

"We are delighted to deliver our 500th H-Cube," commented Dr. Laszlo Urge, CEO of ThalesNano Inc. "It is no surprise that this landmark system was acquired by a leading Chinese Institute. China has a worldwide reputation for innovation and efficiency and its scientists always diligently select the best technologies available. Recent purchases by some of the country's biggest companies have really raised awareness of the H-Cube, resulting in China becoming one of our fastest growing markets."

The H-Cube Continuous-flow Hydrogenation Reactor is a bench-top standalone hydrogenation device, uniquely combining continuous-flow microchemistry with endogenous on-demand hydrogen generation and a disposable catalyst cartridge system. Compared to conventional methods, it allows safer, faster and more cost-efficient hydrogenation with superior yield. The H-Cube and the other novel Cube series flow reactor systems developed by ThalesNano Inc. are showing tremendous benefits in the drug discovery process including shortened development time, increased cost efficiency and reduced environmental impact.

For more information please go to: www.thalesnano.com

About ThalesNano Inc.:

ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube® continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Midi™ are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation.

About Beijing Institute of Technology:

The institute was founded by Chinese central government in 1958. It initially produced penicillin starin in China and has since become the major state institute in China for drugs acting against infectious diseases and other major human diseases. There are 400 people working at the institute.


Contact:
Laszlo Urge, Ph.D., CEO
e-mail: Email Contact
Telephone: +36-1-880-8500



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES